- Church & Dwight Co., Inc. recently reported first-quarter 2026 results showing sales of US$1,469.3 million and net income of US$216.3 million, affirmed a quarterly dividend of US$0.3075 per share, and issued guidance for a 1% reported sales decline for the June 2026 quarter due to prior portfolio actions.
- Management highlighted that growth in key brands such as ARM & HAMMER and THERABREATH, alongside online sales reaching nearly 24% of global consumer sales, is supporting underlying performance despite flat overall revenue.
- We’ll now examine how this mix of volume-led organic growth and expanding e-commerce weight could reshape Church & Dwight’s investment narrative.
The future of work is here. Discover the 32 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
Church & Dwight Investment Narrative Recap
To own Church & Dwight, you need to believe its core brands and growing online presence can offset slower categories and cost pressures. The latest quarter broadly supports that view, with volume-led growth in ARM & HAMMER and THERABREATH helping to counter flat reported sales, while near term guidance for a 1% sales decline looks more like a continuation of prior portfolio pruning than a new, thesis-breaking setback. The biggest near term risk remains ongoing category weakness and pricing pressure in lagging franchises.
The most relevant recent announcement is the reaffirmed quarterly dividend of US$0.3075 per share. For many shareholders, that steady cash return matters when reported sales are essentially flat and guidance points to a modest decline next quarter. It suggests management is comfortable maintaining current capital returns even as it absorbs revenue dilution from past exits and leans on e commerce and premium brands as key catalysts to support the longer term story.
Yet investors should not ignore how pressure on underperforming categories and retailer promotions could still affect Church & Dwight’s margins and capital allocation...
Read the full narrative on Church & Dwight (it's free!)
Church & Dwight's narrative projects $6.6 billion revenue and $969.0 million earnings by 2029.
Uncover how Church & Dwight's forecasts yield a $101.53 fair value, a 8% upside to its current price.
Exploring Other Perspectives
Before this print, the most optimistic analysts were banking on revenue reaching about US$6.7 billion and earnings near US$995 million, which is a much rosier setup than the baseline view that focuses on steadier e commerce growth and brand resilience. When you weigh those bullish expectations against fresh guidance for a 1 percent sales decline and ongoing category risks, it underlines how wide opinion can be and why it is worth exploring how both narratives might shift from here.
Explore 5 other fair value estimates on Church & Dwight - why the stock might be worth just $101.53!
Reach Your Own Conclusion
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Church & Dwight research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
- Our free Church & Dwight research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Church & Dwight's overall financial health at a glance.
Curious About Other Options?
Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:
- The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
- Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.
- AI is about to change healthcare. These 35 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com